Mushroom progress! MindMed Moves Towards Phase 2 Microdosing LSD Trial for ADHD in Adults

Secondary market MindMed (NEO: MMED) announced that they have entered into a clinical trial agreement with Maastricht University to undertake a phase 2a clinical trial of lysergic acid diethylamide (LSD) in adult patients with attention deficit hyperactivity disorder (ADHD).

As per the agreement, Maastricht University will provide facilities and personnel for the Phase 2a proof of concept clinical trial for MindMed’s multicenter, randomized, double-blind, placebo-controlled safety trial. and the effectiveness of low-dose LSD as a treatment for ADHD in adults. .

The company will now move to an LSD microdosing program with Dr Kuypers and the Liechtenstein laboratory at the University Hospital Basel. They are currently in the regulatory ethics submission process in the Netherlands and plan to start the Phase 2a clinical trial by the end of the year. In order to create a portfolio of clinical trials investigating the use of subperceptual amounts of psychedelics for medical purposes, the company has created a microdosing division.

MindMed stock closed today up 3c to 60c.

Information for this briefing was found via Sedar and MindMed. The author has no title or affiliation related to this organization. Not a buy or sell recommendation. Always do additional research and consult a professional before purchasing a title. The author does not hold any license.

Source link

About Daniel Lange

Daniel Lange

Check Also

Car crashes through UK house wall to reveal illegal weed cultivation

Breadcrumb Links World news New Legalization South Wales Police were initially dispatched to the scene …

Leave a Reply

Your email address will not be published. Required fields are marked *